Literature DB >> 33438350

Early-onset interstitial pneumonitis in a patient with advanced non-small cell lung cancer treated with crizotinib and osimertinib.

Yuan Cheng1, Qing Yu1, Yan Xiong2, Cuiyan Guo1, Ligong Nie1.   

Abstract

Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non-small cell lung cancer (NSCLC). Here, we report the case of a 60-year-old male patient with advanced NSCLC resistant to osimertinib. Crizotinib was administered in combination with osimertinib due to elevated mesenchymal epithelial transition (MET) copy number amplification. However, early-onset interstitial pneumonitis occurred within two days.
© 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Crizotinib; NSCLC; Osimertinib; early-onset interstitial pneumonitis

Mesh：

Substances：

Year:  2021        PMID： 33438350      PMCID： PMC7919124          DOI： 10.1111/1759-7714.13785

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN： 1759-7706            Impact factor:   3.500


  6 in total

1.  Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials.

Authors:  Wei-Xiang Qi; Yuan-Jue Sun; Zan Shen; Yang Yao
Journal:  J Chemother       Date:  2014-04-14       Impact factor: 1.714

2.  Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

Authors:  Dong-Wan Kim; Marcello Tiseo; Myung-Ju Ahn; Karen L Reckamp; Karin Holmskov Hansen; Sang-We Kim; Rudolf M Huber; Howard L West; Harry J M Groen; Maximilian J Hochmair; Natasha B Leighl; Scott N Gettinger; Corey J Langer; Luis G Paz-Ares Rodríguez; Egbert F Smit; Edward S Kim; William Reichmann; Frank G Haluska; David Kerstein; D Ross Camidge
Journal:  J Clin Oncol       Date:  2017-05-05       Impact factor: 44.544

3.  Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non-Small Cell Lung Cancer: Independent Review of Four PROFILE Trials.

Authors:  Ken Y Yoneda; Judith R Scranton; Michael A Cadogan; Vanessa Tassell; Sashi Nadanaciva; Keith D Wilner; Nicholas S Stollenwerk
Journal:  Clin Lung Cancer       Date:  2017-03-14       Impact factor: 4.785

4.  Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.

Authors:  Chong Hyun Suh; Hye Sun Park; Kyung Won Kim; Junhee Pyo; Hiroto Hatabu; Mizuki Nishino
Journal:  Lung Cancer       Date:  2018-06-30       Impact factor: 5.705

5.  The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.

Authors:  Yubo Wang; Panwen Tian; Lei Xia; Li Li; Rui Han; Mengxiao Zhu; Analyn Lizaso; Tian Qin; Min Li; Bing Yu; Xinru Mao; Han Han-Zhang; Yong He
Journal:  Lung Cancer       Date:  2020-06-06       Impact factor: 5.705

6.  Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.

Authors:  Wenxian Wang; Hong Wang; Peihua Lu; Zongyang Yu; Chunwei Xu; Wu Zhuang; Zhengbo Song
Journal:  J Transl Med       Date:  2019-02-21       Impact factor: 5.531
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.